Wednesday, October 28, 2020

Asieris' APL-1501 Approved for Phase I Clinical Trial in Australia

SHANGHAI, Oct. 28, 2020 /PRNewswire/ -- Asieris Pharmaceuticals, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, today announced that Australian regulatory authorities have...



from PR Newswire: https://ift.tt/3mBlGBn

No comments:

Post a Comment